Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.79 CAD | +1.05% | 0.00% | +11.56% |
03-22 | Knight Therapeutics Price Target Raised to $7 at RBC | MT |
03-21 | Knight Therapeutics Reports Fourth Quarter Results | MT |
Business Summary
Number of employees: 725
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products, Consumer Health Products and Medical Devices
100.0
%
| 294 | 100.0 % | 328 | 100.0 % | +11.80% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Brazil
51.3
%
| 135 | 45.9 % | 168 | 51.3 % | +24.86% |
Rest of Latin America
16.8
%
| 40 | 13.7 % | 55 | 16.8 % | +37.17% |
Colombia
13.6
%
| 46 | 15.7 % | 45 | 13.6 % | -3.24% |
Argentina
7.3
%
| 48 | 16.4 % | 24 | 7.3 % | -49.95% |
Canada
6.0
%
| 11 | 3.9 % | 20 | 6.0 % | +73.39% |
Other
5.0
%
| 13 | 4.4 % | 16 | 5.0 % | +26.27% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Samira Sakhia
CEO | Chief Executive Officer | 55 | 31/10/13 |
Jonathan Goodman
FOU | Founder | 56 | 31/10/13 |
Arvind Utchanah
DFI | Director of Finance/CFO | - | 19/06/16 |
Leopoldo Bosano
COO | Chief Operating Officer | - | - |
Monica Percario
CTO | Chief Tech/Sci/R&D Officer | - | - |
Susan Emblem
HRO | Human Resources Officer | - | 30/09/20 |
Amal Khouri
PRN | Corporate Officer/Principal | - | 31/07/14 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Gale
BRD | Director/Board Member | 74 | 05/01/14 |
Jonathan Goodman
FOU | Founder | 56 | 31/10/13 |
Robert N. Lande
BRD | Director/Board Member | 61 | 31/12/12 |
Samira Sakhia
CEO | Chief Executive Officer | 55 | 31/10/13 |
Director/Board Member | 48 | 31/12/19 | |
Michael Tremblay
BRD | Director/Board Member | 71 | 31/12/18 |
Janice Murray
BRD | Director/Board Member | 58 | 31/12/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 101,186,861 | 54,193,855 ( 53.56 %) | 0 | 53.56 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
1,153,897 | 10.42% | 301,167 $ |
Company contact information
Knight Therapeutics, Inc.
3400 de Maisonneuve West Suite 1055
H3Z 3B8, Montréal
+514-484-4483
http://www.gud-knight.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.56% | 429M | |
+4.06% | 69.85B | |
+11.77% | 8.98B | |
-14.44% | 4.89B | |
+41.60% | 4.44B | |
+5.96% | 3.95B | |
+23.46% | 2.49B | |
-19.32% | 2.4B | |
-27.04% | 2.28B | |
+7.97% | 1.96B |
- Stock Market
- Equities
- GUD Stock
- Company Knight Therapeutics Inc.